



261 Mountain View Dr  
 Colchester, VT 05446  
 License #: TLAB0030  
 802-767-7256  
 info@onwardanalytics.biz

# Certificate of Analysis

**Client Name:** Vermont Kind  
**License Number:** SCLT0186

**Sample ID:** VT12778  
**Sample Name:** Anthomancer Virgin Extract  
**Sample Lot:** MANU0027-C0071  
**Sample Matrix:** Solvent Extraction Concentrates  
**Date Received:** 8/30/2024  
**Date Reported:** 9/9/2024  
**Date Tested:** 9/3/2024



## Total Terpenes (%) : 5.0617

### Dominant Terpenes (%)

beta-caryophyllene	2.1059
Limonene	0.8662
alpha-Humulene	0.6596
alpha-Bisabolol	0.3192
Myrcene	0.2688

## Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #39042

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.3192	3.192	0.000003	0.001
alpha-Humulene	0.6596	6.596	0.000002	0.001
alpha-Pinene	0.2005	2.005	0.000001	0.001
alpha-Terpinene	ND	ND	0.000001	0.001
alpha-Terpinolene	0.0707	0.707	0.000004	0.001
beta-caryophyllene	2.1059	21.059	0.000004	0.001
beta-Pinene	0.1515	1.515	0.000002	0.001
Camphene	0.0224	0.224	0.000001	0.001
Caryophyllene Oxide	0.0683	0.683	0.000011	0.001
Eucalyptol	0.0128	0.128	0.000002	0.001
gamma-Terpinene	< LOQ	< LOQ	0.000002	0.001
Geraniol	ND	ND	0.000008	0.003
Guaiol	< LOQ	< LOQ	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.8662	8.662	0.000002	0.001
Linalool	0.1802	1.802	0.000003	0.001
Nerolidol	0.0634	0.634	0.000007	0.001
Myrcene	0.2688	2.688	0.000003	0.001
Ocimene	0.0722	0.722	0.000002	0.001
<b>Total Terpenes</b>	<b>5.0617</b>	<b>50.617</b>		



*Callie Chapman*

Callie Chapman  
 Lab Director  
 9/9/2024

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

